Novartis
ADAKVEO
Manufacturer:
Novartis
Name:
ADAKVEO
HCPCS Code Descriptor:
Injection, crizanlizumab-tmca, 5 mg
Category:
J Code
HCPCS:
J0791
NDC(s):
00078-0883-61
Primary Type:
Oncology-Anti-Emetic
Generic Status:
Single-Source
Route of Administration:
Intravenous
About:
ADAKVEO is an Oncology-Anti-Emetic drug manufactured by Novartis and administered via the Intravenous route of administration. The J Code: J0791 is aligned to the drug ADAKVEO.
Access Pricing and More By Registering
HCPCS Added Date:
7/1/20
HCPCS Effective Date:
7/1/20
HCPCS Short Description:
Inj crizanlizumab-tmca 5mg
Billing and Coding Guide:
https://www.hcp.novartis.com/globalassets/migration-root/hcp/products2/adakveo/resources/billing-coding-guide.pdf
Patient Assistance:
https://www.patient.novartisoncology.com/financial-assistance/pano/
https://copay.novartisoncology.com/